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Melanoma is the deadliest skin cancer due to its high
rate of metastasis, frequently to the brain. Brain me-
tastases are incurable; therefore, understandingmel-
anoma brain metastasis is of great clinical impor-
tance. We used a mouse model of spontaneous
melanoma brain metastasis to study the interactions
of melanomas with the brain microenvironment. We
find that CXCL10 is upregulated in metastasis-asso-
ciated astrocytes in mice and humans and is func-
tionally important for the chemoattraction of mela-
noma cells. Moreover, CXCR3, the receptor for
CXCL10, is upregulated in brain-tropic melanoma
cells. Targeting melanoma expression of CXCR3 by
nanoparticle-mediated siRNA delivery or by shRNA
transduction inhibits melanoma cell migration and
attenuates brain metastasis in vivo. These findings
suggest that the instigation of pro-inflammatory
signaling in astrocytes is hijacked by brain-metasta-
sizing tumor cells to promote their metastatic capac-
ity and that the CXCL10-CXCR3 axis may be a poten-
tial therapeutic target for the prevention ofmelanoma
brain metastasis.
INTRODUCTION
Malignant melanoma is the deadliest of all skin cancers (Ankeny
et al., 2018; Arnold et al., 2014). The major cause of melanoma
mortality is its high metastasis rate to distant organs, frequently
to the brain (Nayak et al., 2012). Brain metastases are incurable
and are associated with a dismal survival. The incidence of brain
metastasis has increased in recent years as a result of improved
diagnostic imaging of smaller, asymptomatic brain metastases
and improved control of extracranial disease by systemic ther-Cell Re
This is an open access article under the CC BY-Napy, enabling the emergence of otherwise not clinically mani-
fested metastases (Nayak et al., 2012; Wang et al., 2017).
Metastasis is a multistage process, facilitated by the microen-
vironment (Joyce and Pollard, 2009). Multiple studies have
demonstrated that changes in the metastatic microenvironment
precede clinically relevant metastases (Erez and Coussens,
2011; Joyce and Pollard, 2009; Peinado et al., 2017). Tumor cells
were shown to induce the reprogramming of cells in themicroen-
vironment to form a hospitable metastatic niche by paracrine
and systemic secretion of soluble factors and exosomes (Hosh-
ino et al., 2015; Peinado et al., 2011, 2017). However, changes in
the brain microenvironment that enable metastatic seeding and
growth are poorly understood.
The brain encompasses a unique microenvironment that
maintains the physiological homeostasis and orchestrates the
response to pathological dysregulations, including cancer (Va-
liente et al., 2018). One of the central components of the brain
microenvironment are astrocytes, glial cells that perform many
functions in maintaining brain homeostasis and that play a prin-
cipal role in tissue repair processes. Following brain insult, astro-
cytes are activated in a response called astrogliosis, character-
ized by the upregulation of glial fibrillary acidic protein (GFAP),
increased production and remodeling of intermediate filament
proteins (Pekny et al., 2014), and upregulation of pro-inflamma-
tory cytokines and chemokines (Doron et al., 2019). Astrocyte
activation and neuroinflammation can be driven by activated mi-
croglia and immune cells (Liddelow and Barres, 2017; Liddelow
et al., 2017) and are characterized by the release of pro-inflam-
matory mediators, increased blood-brain barrier permeability,
and leukocyte infiltration (Burda and Sofroniew, 2014). While
much data have accumulated on the role of astrogliosis and neu-
roinflammation in neurodegenerative and autoimmune diseases
in the CNS (Skaper et al., 2018), the role of neuroinflammation in
brain tropism and metastasis is largely unknown.
Astrocytes were shown to support the growth and infiltration
of tumor cells in the brain parenchyma by various mechanisms
(Chuang et al., 2013b; Kim et al., 2011; Lin et al., 2010; Placoneports 28, 1785–1798, August 13, 2019 ª 2019 The Author(s). 1785
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Astrocytes Are Activated by Melanoma Cells to Express and Secrete Pro-inflammatory Cytokines In Vitro and In Vivo
(A) Scheme of astrocyte activation: normal astrocytes are incubated with RMS-CM, washed, and incubated with fresh SFM to produce activated astrocyte-CM.
SFM, serum-free medium; CM, conditioned medium. Isolation and purity analyses of cultured astrocytes are shown in Figures S1A–S1E.
(legend continued on next page)
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et al., 2016). Moreover, astrocytes were implicated in supporting
the growth of brain-metastasizing tumor cells via pro-inflamma-
tory signaling (Klein et al., 2015; Priego et al., 2018; Schwartz
et al., 2016), but the underlying mechanisms remain unresolved.
Wepreviously established amousemodel of spontaneousmel-
anoma brain metastasis. Thismodel, based on the subdermal im-
plantation of melanoma cells (RMS cells, derived from Ret-mela-
noma transgenic mice), recapitulates the pathological multistep
process of spontaneous metastasis following surgical removal
of the primary tumor (Schwartz et al., 2016). We found that astro-
gliosis and neuroinflammation are instigated during the formation
of brain micrometastases and that astrocytes facilitate the initial
growth of melanoma cells in the brain. Furthermore, we showed
that the chemokine CXCL10, known to be upregulated during
gliosis (Zamanian et al., 2012), is upregulated in the brainmetasta-
tic microenvironment. CXCL10 belongs to the CXC chemokine
family and is a ligand of the CXCR3 receptor. CXCL10 is secreted
in response to interferon-g (IFN-g) by various cell types, including
monocytes, endothelial cells, fibroblasts, and astrocytes, and
was shown to modulate the migration of monocytes, macro-
phages, T cells, and natural killer (NK) cells (Metzemaekers
et al., 2018). Moreover, CXCL10 levels are elevated in advanced
melanoma patients and were associated with poor clinical out-
comes (Jiang et al., 2015; Wightman et al., 2015). We therefore
hypothesized that astrocyte-derived CXCL10 may be involved
in facilitating melanoma brain tropism and metastasis.
Here, we show that the chemokine CXCL10 is upregulated in
metastases-associated astrocytes, and its secretion is function-
ally important for the astrocyte-mediated chemoattraction of
melanoma cells. Moreover, we found that the CXCL10 receptor
CXCR3 is upregulated in brain-tropic melanoma cells, and that
targeting its expression resulted in the inhibition of melanoma
brain metastasis.
RESULTS
CXCL10 Is Upregulated in Metastasis-Associated
Astrocytes
We previously demonstrated that astrocytes are activated by
melanoma-secreted factors to upregulate the expression of mul-(B and C) Cytokine array analysis (B) and representative membrane blots (C) of
trocytes were activated as in (A), lysed, and hybridized with the mouse cytokine
(D) ELISA of CXCL10 in normal or activated astrocyte-CM, representative of n = 3
duplicates; one-tailed Student’s t test; *p = 0.0260.
(E) Sorting strategy for metastases-associated astrocytes. The ACSA-2 antibody w
brains following intracardiac or intracranial injections. The purity analysis of sorte
(F) Cxcl10 expression was analyzed by qPCR and the results were normalized t
experiments, n = 4 pooled brains in each. The data are presented as means ± S
(G) Co-staining of astrocytes (GFAP, magenta) and CXCL10 (green) in brain mac
bar, 50 mm. At right, only the magenta and green channels are shown.
(H) Spontaneous melanoma brain metastasis model scheme.
(I) Co-staining of astrocytes (GFAP, magenta) and CXCL10 (green) in spontaneou
only the magenta and green channels are shown.
(J) Co-staining of astrocytes (GFAP, magenta) and CXCL10 (green) in spontaneou
magenta and green channels are shown in the center. The 3D maximal projectio
(K) Co-staining of astrocytes (GFAP, green) and CXCL10 (red) in human tissue sec
scale bar represents 100 mm. Right: digital enlargement of center image. Repres
(G–J) White, colocalization of astrocytes (magenta) with CXCL10 (green). At righ
rectangles are shown. The images are representative of multiple fields analyzedtiple pro-inflammatory factors, including CXCL10 (Schwartz
et al., 2016). To investigate pro-inflammatory reprogramming
of astrocytes by melanoma cells, we performed experiments
with primary astrocytes, isolated from normal adult mice (Fig-
ure S1A). Analysis of cultured astrocytes by immunostaining,
qPCR, and fluorescence-activated cell sorting (FACS) confirmed
the purity of isolated astrocytes. Astrocyte cultures did not
contain immune cells or microglia (Figures S1B–S1E). We then
analyzed the expression of multiple inflammatory mediators in
astrocytes activated by incubation with melanoma-secreted
factors using a cytokine array. We found that CXCL10 was the
most highly upregulated factor in activated astrocytes (Figures
1A–1C). Control non-activated astrocytes had almost no basal
CXCL10 expression, in agreement with our previous observa-
tions at the mRNA level (Schwartz et al., 2016). Analysis of
CXCL10 secretion by ELISA confirmed that CXCL10 was highly
secreted by activated astrocytes compared to normal astrocytes
(Figure 1D). We next set out to assess whether CXCL10 is
expressed in metastases-associated astrocytes (MAAs)
in vivo. To that end, we isolated MAAs by FACS sorting of
mCherryCD45ACSA-2+ cells from the brains of mice bearing
macrometastases from intracardiac or intracranial injections
(Figures 1E and S1F). The purity of sorted astrocytes was vali-
dated by analyzing the expression of cell-specific markers (Fig-
ure S1G). Expression analysis of sorted cells revealed that
Cxcl10 was highly upregulated in MAAs compared with normal
astrocytes (Figure 1F). To further validate the expression of
CXCL10 in MAAs in vivo, we performed co-staining of CXCL10
and GFAP in melanoma lesions arising in the brains of mice
that were injected intracranially, as compared with normal
brains. Analysis of the results revealed that reactive astrocytes
adjacent to melanoma cells expressed CXCL10 (Figures 1G,
S2A, and S2B). We also validated the expression of CXCL10 in
MAAs in our established model of spontaneous brain metastasis
(Figure 1H). Brains bearing spontaneous metastases showed
CXCL10 expression in astrocytes already in micrometastases
(Figures 1I, S2C, and S2D). The expression of CXCL10 was
evident also in MAAs adjacent to spontaneous macrometasta-
ses (Figure 1J), suggesting that CXCL10 plays a role throughout
different stages of metastasis formation. Notably, while CXCL10pro-inflammatory factors in activated astrocytes and normal astrocytes. As-
array panel. In (C), box indicates CXCL10; n = 2.
independent experiments. The data are presented as means ± SDs of technical
as used to isolate astrocytes from normal brains or macrometastases-bearing
d astrocytes is shown in Figures S1F and S1G.
o Hprt and to the normal control group. Representative of n = 2 independent
Ds of technical repeats; two-tailed Student’s t test; *p = 0.0329.
rometastases following intracranial injections (melanoma, mCherry red). Scale
s brain micrometastases (melanoma, mCherry red). Scale bar, 25 mm. At right,
s brain macrometastases (melanoma, mCherry red). Scale bar, 50 mm. Only the
n is shown at right.
tions of melanoma brain metastases. Left: scale bar represents 400 mm.Center:
entative of multiple fields analyzed from n = 2 patients.
t in (G) and (I) and center in (J) digital enlargement of areas designated with
from n = 3 mice per group. Additional images are shown in Figures S2A–S2D.
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and GFAP stainings overlapped, they were not completely
aligned, as GFAP is a cytoskeletal marker and CXCL10 is a cyto-
plasmatic or secreted protein (Figure 1J, right panel). Finally, we
asked whether CXCL10 expression in astrocytes is relevant to
human melanoma brain metastasis. To that end, we analyzed
frozen specimens obtained from patients undergoing surgical
resection of melanoma brain metastases. Co-staining with
GFAP and CXCL10 confirmed that CXCL10 is expressed in as-
trocytes infiltrating metastatic melanoma lesions (Figure 1K).
Similar to our findings in the mouse model, CXCL10 was ex-
pressed in human melanoma brain metastatic cells. These
results support our findings that CXCL10 expression is charac-
teristic of inflammatory astrocytes in brain metastasis, and it
encouraged us to further unravel its functional role.
CXCL10 Is Functionally Necessary for Astrocyte-Driven
Melanoma Cell Migration
CXCL10 is a known T cell chemoattractant, operating via its
cognate receptor CXCR3 (Metzemaekers et al., 2018). Astro-
cytes were recently shown to orchestrate T cell recruitment to
the brain via their CXCL10 secretion in multiple sclerosis (Cheng
and Chen, 2014; Sørensen et al., 2002) and during viral CNS in-
fections (Phares et al., 2013). We therefore hypothesized that
melanoma cells hijack this physiological pathway, resulting in
the brain tropism of brain-metastasizing melanoma cells. To
test our hypothesis, we characterized the role of astrocyte-
derived CXCL10 in mediating the chemoattraction of melanoma
cells to the brain. To that end, we established a spontaneous
brain-seeking melanoma cell line by injecting mice subdermally
with RMS cells. Primary tumors were surgically removed, and
melanoma cells from ensuing spontaneous melanoma brain
and lung macrometastases were isolated and cultured. These
cells were designated sBT-RMS (spontaneous brain-tropic
RMS) and sLT-RMS (spontaneous lung-tropic RMS), respec-
tively (Figure 2A). To assess the brain-infiltrating capacity of
the metastatic variants, we used an ex vivo 3-dimensional (3D)
organotypic model that allows the quantification of tumor cell
infiltration to the brain parenchyma (Figure S2E; Chuang et al.,Figure 2. Astrocyte-Derived CXCL10 Facilitates Melanoma Cell Migrat
(A) Illustration of sBT-RMS and sLT-RMS cell isolation.
(B) Representative images of the organotypic co-culture with RMS, sBT-RMS, a
tumor plugs. Scale bars, 30 mm. Melanoma cells (mCherry, red), astrocytes (GFAP
corresponding lower magnifications shown in Figures S2E and S2F.
(C) Quantification of the relative infiltration of the different cell lines. RMS: n = 16
(D and E) Analysis of sBT-RMS brain-metastatic potential in vivo, compared to par
per group were injected and excluded from analysis if lungmacrometastases or pr
kinetics of RMS or sBT-RMS-injected mice. The data are presented as means
determinant of brain metastatic load, showing the percentage of mice with brain
analysis of the lung metastasis is shown in Figures S2G and S2H.
(F) Transwell assay experimental design, 48 h migration.
(G) Representative images of RMS migration toward control (SFM), astrocytes (A
(H) Quantification of (G); the data are presented as means ± SEMs of 45 fields pe
with Tukey’s post hoc test; ****p < 0.0001.
(I) Representative images of RMS and sBT-RMS migration toward SFM, astrocy
(J) Quantification of (I); the data are presented asmeans ±SEMs of 30 fields per tre
Tukey’s post hoc test; **p < 0.002, ***p < 0.0005, and ****p < 0.0001.
(K) Representative images of sh1-CXCL10 and sh2-CXCL10 migration toward S
(L) Quantification of K; the data are presented asmeans ±SEMs of 30 fields per tre
Tukey’s post hoc test; ****p < 0.0001. CXCL10 silencing validation and the scram2013a; Schwartz et al., 2016). Analysis of the results revealed
that sBT-RMS cells exhibited a higher capacity to infiltrate the
brain parenchyma compared with the RMS parental melanoma
cell line. This infiltrative capacity was brain specific, as the infil-
tration of the lung-tropic variant was significantly lower (Figures
2B, 2C, and S2F). To further validate the brain tropism of the
newly isolated sBT-RMS cells compared to RMS cells in vivo,
we injected the cells subdermally. Notably, analysis of primary
tumor growth indicated similar growth kinetics (Figure 2D). Anal-
ysis of brain metastatic load indicated that sBT-RMS-injected
mice developed more brain micrometastases compared with
RMS-injectedmice (Figure 2E). This advantage was indeed brain
specific: analysis of lungmetastatic load by gross inspection and
by qPCR analysis indicated that sBT-RMS-injected mice had
fewer lung macrometastases compared to the RMS-injected
group (Figures S2G and S2H). Thus, the establishment of brain
tropism following interactions between melanoma cells and the
brain microenvironment may be organ specific.
We next assessed the functional role of astrocyte-derived
CXCL10 in mediating melanoma cell migration by analyzing the
migration of melanoma cells toward astrocytes in Transwell as-
says. To specifically analyze the functional importance of
CXCL10 in promoting melanoma cell migration, we added
neutralizing antibodies (Figure 2F). We found that CXCL10
neutralization significantly attenuated melanoma cell migration
toward astrocytes, suggesting that astrocyte-induced migration
of melanoma cells is mediated, at least partially, by CXCL10 (Fig-
ures 2G and 2H).
Intrigued by these findings, we asked whether the brain-tropic
nature of the sBT-RMS cell line is dependent on CXCL10. To that
end, we tested the migration capacity of the sBT-RMS cell line
toward astrocytes as compared with RMS cells. We found that
both RMS and sBT-RMS cells exhibited increased migration to-
ward astrocytes compared to the serum-free media (SFM) con-
trol and that sBT-RMS cells had a significantly enhanced capac-
ity to migrate toward astrocytes. This effect was inhibited by the
addition of CXCL10-neutralizing antibodies (Figures 2I and 2J).
Thus, the enhanced brain-metastatic capacity of the sBT-RMSion
nd sLT-RMS cell lines infiltrating the brain slice and astrocytes protruding into
, green), and microglia (isolectin B4 [ILB4], magenta). Experiment scheme and
, sBT-RMS: n = 26, sLT-RMS: n = 15. Chi-square test, *p = 0.02.
ental RMS cells, using the spontaneous model shown in Figure 1H. n = 12mice
imary tumor recurrences formed before the endpoint. (D) Primary tumor growth
± SEMs; n.s., not significant. (E) qPCR analysis of mCherry expression as a
micrometastases. RMS: n = 6, sBT-RMS: n = 11, normal controls: n = 3. The
ST), or astrocytes +anti-CXCL10 antibody (Ab.); scale bars, 500 mm.
r treatment group from n = 3 independent biological repeats. One-way ANOVA
tes, or astrocytes +anti-CXCL10 Ab.; scale bars, 500 mm.
atment group from n = 3 independent biological repeats. Two-way ANOVAwith
FM, astrocytes, and astrocytes +anti-CXCL10 Ab.; scale bars, 150 mm.
atment group from n = 3 independent biological repeats. Two-way ANOVAwith
ble control migration experiment are shown in Figures S2I and S2J.
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cells may be mediated by astrocyte-derived CXCL10 signaling.
Since melanoma cells also express CXCL10 (Harlin et al.,
2009; Mauldin et al., 2015), we wanted to specifically analyze
the functional importance of astrocyte-derived CXCL10 for
melanoma cell migration. To that end, we knocked down the
expression of CXCL10 in melanoma cells by lentiviral transduc-
tion of CXCL10-targeting small hairpin RNA (shRNA), so that as-
trocytes are the only source of CXCL10 in the Transwell migra-
tion assays. CXCL10 knockdown (KD) was confirmed by qPCR
analysis of the CXCL10-KD variants (sh1- and sh2-CXCL10
RMS cells) compared to the scramble-infected (SC-RMS) con-
trol cells (Figure S2I). Transwell migration assays indicated that
inhibiting the function of astrocyte-derived CXCL10 with neutral-
izing antibodies significantly attenuated tumor cell migration
(Figures 2K and 2L), further confirming the central role of astro-
cyte-derived CXCL10. SC-RMS cells had a higher overall migra-
tion compared with CXCL10-KD cells (Figure S2J), demon-
strating the role of autocrine CXCL10 signaling in enhancing
the migration of melanoma cells. Thus, while melanoma auto-
crine CXCL10 signaling can mediate cell migration, we show
that astrocyte-derived CXCL10 is functionally important in
enhancing melanoma migration.
CXCR3 Is Highly Expressed in Brain-Tropic Melanoma
Cells and Is Functionally Important in Facilitating
Melanoma Cell Migration
TheCXCL10-CXCR3 axis was previously shown to be involved in
the tropism of melanoma cells to the lungs (Wightman et al.,
2015). However, the role of astrocyte-derived CXCL10 in facili-
tating brain tropism via this signaling axis is unknown. Thus,
we compared CXCR3 expression in the parental cell line (RMS)
with organ-tropic variants, including a brain-tropic variant (BT-
RMS) that we previously established by serial intracardiac injec-
tions (Schwartz et al., 2016), and the spontaneous brain-tropic
and lung-tropic melanoma cells (sBT-RMS and sLT-RMS,Figure 3. CXCR3 Is Highly Expressed in Brain-Tropic Melanoma Cells
(A) qPCR analysis of Cxrc3 in the different RMS variants in vitro. The results were
n = 3 independent repeats. One-way ANOVA with Tukey’s post hoc test; *p = 0.
(B) FACS analysis of CXCR3 in cultured RMS and sBT-RMS cells. Representative
Figure S3A. SSC, side scatter.
(C) qPCR analysis of Cxcr3 silencing validation in the CXCR3-KD cell lines. Th
means ± SEMs of the biological repeats from n = 5 experiments. One-way ANOV
(D) FACS analysis of CXCR3 expression in cultured SC-RMS and sh2-CXCR3 cells
in Figure S3B. FSC, forward scatter.
(E) CXCR3 expression in the total cell population presented as a quantification of
the measurements from n = 2 independent repeats. The results were normalize
**p = 0.0024.
(F) Representative images of sh1-CXCR3 and sh2-CXCR3 migration toward SFM
(G) Quantification of (F). The data are presented as means ± SEMs of 30 fields f
****p < 0.0001.
(H) Co-staining of astrocytes (GFAP, green) and CXCR3 (red) in human tissue se
multiple fields analyzed from n = 2 patients.
(I) Scheme of the amphiphilic aminated poly(a)glutamate cationic-based polyme
(J) Representative qPCR analysis of Cxcr3 in RMS cells incubated with polyple
negative control siRNA (APA:siRNA EGFP). The results were normalized to Hprt a
repeats; n = 2 independent repeats. One-way ANOVA with Tukey’s post hoc tes
(K) Representative migration images of RMS cells treated with the polyplex targe
(L) Quantification of (K). The data are presented as means ± SEMs of the technica
post hoc test; **p = 0.0042 and ****p < 0.0001. Additional data on the polyplexesrespectively). qPCR analysis revealed that the brain-tropic vari-
ants of melanoma expressed higher levels of Cxcr3 compared
to the parental cells (Figure 3A). Analysis at the protein level by
FACS confirmed that a subpopulation of sBT-RMS cells express
higher levels of CXCR3 compared to RMS (Figures 3B and S3A).
Thus, CXCR3 is upregulated in brain-tropic cells, suggesting that
this chemokine receptor has a functional role in the capacity of
melanoma cells to metastasize to the brain. To investigate the
functional role of CXCR3 in melanoma brain tropism, we
knocked down its expression by lentiviral transduction in RMS
cells. Analysis of knockdown efficacy at the RNA level confirmed
a significant silencing ofCxcr3 expression (Figure 3C), and FACS
analysis verified the downregulation of CXCR3 (Figures 3D, 3E,
and S3B), providing us with an experimental tool to further study
the functional role of CXCR3 in mediating melanoma cell migra-
tion and brain metastasis. We next performed a migration assay
and found that themigration of CXCR3-KD RMS cells toward as-
trocytes was strongly attenuated compared to the SC-RMS con-
trol (Figures 3F and 3G), confirming that melanoma cell migration
is mediated by the CXCL10-CXCR3 axis. Immunostaining of tis-
sue samples from patients with melanoma brain metastases
showed that CXCR3 is expressed in human brain metastatic
melanoma cells, suggesting that this signaling axis plays a role
in human disease (Figure 3H).
Based on these findings, we next askedwhether CXCR3 could
be a potential therapeutic target to inhibit melanoma migration
and metastasis. For therapeutic targeting, we used amphiphilic
polyplex nanocarriers, which were recently shown to be effective
for the systemic administration of RNAi to tumors (Krivitsky et al.,
2018; Polyak et al., 2017). Moreover, the amphiphilic polygluta-
mate amine (APA) polymeric nanocarrier complexed with a com-
bination of miR-34a and small interfering RNA (siRNA) targeting
PLK1 was demonstrated to be therapeutically functional in a
mousemodel of orthotopic pancreatic cancer by inhibiting tumor
growth and prolonging survival (Gibori et al., 2018). Here, weand Is Functionally Important for Melanoma Cell Migration
normalized to Hprt and RMS. The data are presented as means ± SEMs from
0267.
of n = 3 independent repeats. Isotype control and gating strategy are shown in
e results were normalized to Hprt and SC-RMS. The data are presented as
A with Tukey’s post hoc test; **p = 0.0024 and ***p = 0.0003.
. Representative of n = 2 repeats. Isotype control and gating strategy are shown
mean fluorescent intensity (DMFI). The data are presented as means ± SEMs of
d to SC-RMS. One-way ANOVA with Tukey’s post hoc test; *p = 0.0322 and
and astrocytes, seeded and analyzed as in Figure 2F. Scale bars, 500 mm.
rom n = 3 independent repeats. Two-way ANOVA with Tukey’s post hoc test;
ctions of melanoma brain metastases. Scale bars, 100 mm. Representative of
r (APA).
xes APA:siRNA-1 CXCR3 or APA:siRNA-2 CXCR3 compared to untreated or
nd the untreated control. The data are presented as means ± SDs of technical
t; **p = 0.003 and ****p < 0.0001.
ting CXCR3, at 103 magnification.
l repeats from n = 2 independent experiments. One-way ANOVA with Tukey’s
are presented in Figures S3C and S3D.
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Figure 4. T Cell Migration Is Facilitated by Astrocyte-Derived CXCL10
(A) T cell (CD3, cyan) staining in normal brain or spontaneous brain macrometastases (melanoma, mCherry red). Scale bars, 50 mm. Representative images from
multiple fields analyzed in n = 2 mice. The white rectangle designates the digital enlarged area shown at right. Right, overlay of the cyan and blue channels.
(B) Purity FACS analysis of cultured splenocytes, using CD3-FITC (fluorescein isothiocyanate) antibody.
(C) Experimental design for T cell migration. The lower chamber contained SFM, normal astrocyte-CM, or CM of astrocytes activated by RMS or sBT-RMS- CM.
Migration was assessed after incubation for 5 h.
(D) Representative images of T cell migration described in (C); scale bar, 200 mm.
(E) Quantification of migrated T cells shown in (D). The data are presented as means ± SEMs of six fields from n = 3 independent repeats. Multiple two-tailed t test
analysis; *p = 0.042, **p < 0.00001, and ***p < 0.000001.
(F and G) Activated astrocyte soluble factors upregulate integrins in melanoma cells.
(legend continued on next page)
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complexed APA with RNAi to silence Cxcr3. Two sequences of
siRNA oligonucleotide sequences targeting Cxcr3 (siRNA-1
and siRNA-2) were used for the complexation with APA (Fig-
ure 3I). Electrophoretic mobility shift assay (EMSA) verified the
formation of the polymer:siRNA polyplexes according to the
number of positively charged amino groups (N) neutralized by
the negative charge of the siRNA phosphates (P). The selected
N:P ratio 2, resulted in nanosized (180 nm) and positively
charged (z potential of+22 mV) polyplexes. The obtained poly-
plex is stable for up to 24 h in plasma, protecting the siRNA from
degradation in the bloodstream (Figure S3C). Both APA:CXCR3
siRNA-1 and siRNA-2 polyplexes significantly reduced the
expression ofCxcr3 compared to the untreated and the negative
control (NC) siRNAs (Figure 3J). Furthermore, the APA:CXCR3-
siRNA polyplexes did not show toxic effects on the viability of
melanoma cells (Figure S3D). The achieved downregulation of
Cxcr3 resulted in a significant inhibition (60%–70%) of mela-
noma cell migration toward astrocytes, compared to the migra-
tion of untreated cells (Figures 3K and 3L), suggesting that tar-
geting CXCR3 on tumor cells may be therapeutically beneficial.
To further elucidate the importance of CXCR3 in facilitating brain
tropism, we engineered the parental RMS cells to overexpress
CXCR3 (Figure S4A) and tested the effect of this enhanced
expression on their capacity to colonize the brain, as compared
with control cells transduced with the backbone plasmid. Anal-
ysis of brain metastases indicated that CXCR3-overexpressing
RMS cells formed more brain macrometastases (Figures S4C
and S4D). sLT cells did not form any brain macrometastases,
even following the overexpression of CXCR3 (Figures S4B and
S4C), suggesting that their reprogramming in the lung microen-
vironment was organ specific, and did not endow them with an
advantage in the brain. These results support our hypothesis
that CXCR3high melanoma cells are better equipped to colonize
the brain.
CXCL10 Secreted fromMelanoma-Activated Astrocytes
Enhances T Cell Migration and Upregulates ITGb4 in
Melanoma Cells
Previous studies demonstrated the presence of T cells in human
melanoma brain metastasis (Amit et al., 2013; Berghoff et al.,
2015b). To assess T cell infiltration to melanoma brain metas-
tasis, we performed immunostaining, which indicated that
CD3+ T cells were associated with spontaneousmelanoma brain
macrometastases, but they could not be detected in normal
brains (Figure 4A). Since CXCL10 is a known chemoattractant
for T cells, we next asked whether pro-inflammatory activation
of astrocytes by melanoma cells facilitates their capacity to re-
cruit T cells. We isolated murine splenocytes and validated their
purity (Figure 4B). We then assessed the capacity of T cells to
migrate toward astrocyte-secreted factors using a Transwell
assay (Figure 4C). T cell migration toward activated astrocyte-
CM (conditioned medium) (activation as in Figure 1A) was(F) qPCR analysis of integrin expression in RMS cells following incubation for 48 h
control of each independent repeat (fold change). The data are presented as mea
**p = 0.0009. A similar experiment with CXCR3-overexpressing cells is shown in
(G) Staining of spontaneous brain micrometastases (melanoma, mCherry red) wi
fields analyzed from n = 3 mice. Additional images are shown in Figure S5B.enhanced compared to their migration toward normal astro-
cyte-CM. Moreover, the activation of astrocytes by secreted
factors of brain-tropic cells (sBT-RMS-CM) gave rise to signifi-
cantly more T cell migration than normal astrocyte-CM, suggest-
ing that the interactions of astrocytes with melanoma cells
activate their physiological tissue damage response, resulting
in the instigation of neuroinflammation. Furthermore, the addi-
tion of CXCL10-neutralizing antibodies significantly inhibited
T cell migration (Figures 4D and 4E), suggesting that astrocyte-
derived CXCL10 is necessary for mediating T cell chemoattrac-
tion, in agreement with its physiological role.
Adhesion molecules were previously shown to participate in
the homing and infiltration of T cells into the brain (Baron et al.,
1993; Denucci et al., 2009; Engelhardt and Ransohoff, 2005).
We hypothesized that these signaling pathways may be hijacked
to facilitate melanoma cell adhesion in the brain. To test this hy-
pothesis and gain mechanistic insights on CXCR3-driven
signaling in promoting brain tropism, we analyzedwhether astro-
cyte-derived factors affected the expression of known adhesion
molecules in melanoma cells. Incubation of melanoma cells with
astrocyte-CM upregulated Cxcr3, Itgb2 (Lfa-1), Itgb4, Itgb5, and
Selplg levels (Figure 4F). To assess whether integrin upregulation
could be downstream of CXCR3, we incubated CXCR3-overex-
pressing RMS cells with activated astrocyte-CM. Analysis of the
results revealed an upregulation of Itgb4 and Itga1 in CXCR3-
overexpressing RMS cells, compared to the parental RMS cells
(Figure S5A). Notably, integrin b4 (ITGb4) and ITGb5 were
recently shown to be expressed in brain organotropic melanoma
cells and exosomes and to mediate breast cancer lung and liver
metastases (Hoshino et al., 2015). We therefore tested whether
ITGb4 is evident in early brain metastasis. Staining of sponta-
neous brain micrometastases specimens indicated that ITGb4
was expressed by metastasizing melanoma cells and by the
associated blood vessels, but not in normal brains (Figures 4G,
S5B, and S5C). These results suggest that the physiological
function of astrocytes in T cell recruitment is hijacked by mela-
noma cells via the upregulation of adhesion molecules in brain-
metastasizing melanoma cells.
CXCR3 Is Functionally Important for the Formation of
Melanoma Brain Metastases In Vivo
Encouraged by the in vitro results, we next investigated the role
of CXCR3 in facilitating brain tropism in vivo. Analysis of CXCR3-
KD cell infiltration in the organotypic ex vivo 3D system demon-
strated that targeting the expression of CXCR3 in melanoma
cells significantly inhibited their capacity to infiltrate brain tissue,
as compared with control cells, suggesting that CXCR3 is an
important mediator of brain colonization (Figures 5A and 5B).
Finally, we investigated the functional importance of CXCR3 in
melanoma brain tropism by analyzing the formation of experi-
mental brain metastasis following the intracardiac injection of
CXCR3-KD RMS or SC-RMS control cells (Figure 5C). The earlywith activated astrocyte-CM. The results were normalized toHprt and the SFM
ns ± SEMs of n = 3 independent experiments, one-tailed t test; *p = 0.0397 and
Figure S5A.
th ITGb4 (green); 2D and 3D maximal projections. Scale bars, 10 mm. Multiple
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formation of macrometastases was assessed by intravital
computed tomography (CT) imaging 9 days after injections,
which indicated that mice injected with CXCR3-KD RMS cells
had fewer metastatic lesions (Figures 5D, S5D, and S5E). Mice
were euthanized the next day, and the gross inspection of brains
confirmed that the inhibition of CXCR3 resulted in fewer macro-
metastases (Figure 5E). Moreover, we histologically validated
the presence of metastases and found that SC-RMS cells
formed larger metastatic lesions, which were associated with
extensive astrogliosis (Figure 5F). Quantitative analysis of brain
metastatic load by qPCR for mCherry was consistent with the
macroscopic observations: CXCR3 knockdown decreased the
occurrence of brain macrometastases by 38%. While 56.5%
of SC-RMS-injected mice developed brain macrometastases,
only 18.2% of the mice injected with CXCR3-KDmelanoma cells
exhibited macrometastatic lesions (Figures 5G and 5H). Our re-
sults implicate the CXCL10-CXCR3 axis in mediating the brain
tropism of melanoma cells via interactions with astrocytes
(Figure 5I).
DISCUSSION
The formation of a hospitable metastatic niche, providing a
growth-promoting environment for metastasizing tumor cells,
is one of the determinants of organ-specific tropism. Astrocytes
are major players in mediating neuroinflammation (Skaper et al.,
2018), but their role in facilitating the formation of brain metasta-
ses is largely unknown. Here, we show that astrocyte-mediated
inflammatory signaling via the CXCL10-CXCR3 axis is function-
ally important for promoting the brain tropism of melanoma.
We demonstrated that melanoma-secreted factors instigate
the pro-inflammatory reprogramming of normal astrocytes
and the upregulation of multiple pro-inflammatory mediators,
including CXCL10. This pro-inflammatory gene signature was
previously shown to be part of a gliosis-related tissue damage
response in astrocytes (Zamanian et al., 2012). Moreover, we
showed CXCL10 upregulation in both murine and human metas-
tases-associated astrocytes in vivo. Notably, CXCL10 expression
was evident in astrocytes that were physically in juxtaposition to
brain-metastasizing melanoma cells and was already detectable
in micrometastases, confirming our previous findings that neuro-
inflammation is an early event during the formation of brainmetas-
tases (Schwartz et al., 2016). CXCL10 was previously demon-Figure 5. CXCR3 Is Functionally Important for the Formation of Melan
(A) Representative images of the organotypic co-culture tumor plug-brain slice i
astrocytes (GFAP, green), and microglia (ILB4, magenta). Scale bars, 20 mm.
(B) Quantification of infiltrated SC-RMS or sh1-CXCR3 cells in (A); n = 12 per gro
(C) Experimental design of intracardiac injections of CXCR3-KD and SC-RMS co
(D) Representative brain CT images (coronal) of mice injected with SC-RMS or CX
CT images are shown in Figures S5D and S5E.
(E) Representative images of brain macrometastases (midsagittal plane). Scale b
(F) Staining of astrocytes (GFAP, digitally colored green) in brain sections of SC
sentative images of multiple fields analyzed from n = 3 mice per group, Scale ba
(G) Brain metastatic load analyzed by qPCR of mCherry. The cutoff for macrome
spection findings (see Method Details). SC-RMS: n = 23, sh1-CXCR3: n = 22, sh
(H) Brain metastasis incidence of mice analyzed in (G): percentages of micro- an
(I) The CXCL10-CXCR3 axis in brain tropism: melanoma soluble factors induce C
and colonization of CXCR3-expressing melanoma cells. This figure was designestrated to be induced in human melanoma cells (Mauldin et al.,
2015), and its levels were found to be elevated in the cerebrospi-
nal fluid (CSF) of patients with melanoma brain metastases (Lok
et al., 2014). However, the functional role of astrocyte-derived
CXCL10 in facilitating brainmetastasis was unresolved.We found
that tumor cell-induced upregulation of CXCL10 in astrocytes re-
sulted in the enhancedmigration of melanoma cells toward astro-
cytes, which was attenuated when CXCL10 was inhibited.
Silencing CXCL10 in melanoma cells also attenuated their migra-
tion. Previous studies implicated autocrine signaling by mela-
noma-derived CXCL10 in tumor progression and metastasis
(Mauldin et al., 2015; Wightman et al., 2015). Thus, the migration
of melanoma cells is mediated via both autocrine and paracrine
signaling by activated astrocytes. Of note, while in vivo CXCL10
may be secreted bymultiple cell types, includingmicroglia, tumor
cells, and astrocytes (Liu et al., 2011), in our in vitro experiments,
astrocytes were the only source of CXCL10. Thus, our findings
confirm the function of astrocyte-derived CXCL10 in the chemo-
attraction of melanoma cells.
To characterize melanoma brain tropism, we generated brain-
tropic cells (sBT-RMS) from spontaneous brain metastases.
When injected orthotopically, sBT-RMS cells were more aggres-
sive in the formation of brain metastases compared to the
parental melanoma cells, confirming their brain tropism in vivo.
Chemokine receptors were previously suggested to be upre-
gulated in brain metastatic melanoma cells (Izraely et al.,
2010). We show that CXCL10 neutralization attenuated the
migration of brain-tropic melanoma cells (sBT-RMS) toward as-
trocytes, and that CXCR3, the receptor of CXCL10, is upregu-
lated in sBT-RMS cells compared with the RMS parental cells.
Moreover, sBT-RMS cells had an advantage in forming brainme-
tastases while forming fewer lung metastases in vivo, indicating
that CXCR3 expression endows melanoma cells with an advan-
tage in forming brain metastases. We further show that abro-
gating the expression of CXCR3 by shRNA transduction or by
nanoparticle-mediated siRNA delivery significantly inhibited
melanoma cell migration toward astrocytes in vitro. Targeting
the expression of CXCR3 profoundly inhibited infiltration into
the brain parenchyma in a 3D ex vivo brain tissue model
and the incidence of brain metastasis in vivo. Furthermore,
CXCR3 overexpression facilitated the formation of metastases
in vivo. These findings implicate a functional role for astrocyte-
derived CXCL10 in facilitating melanoma brain metastasis.oma Brain Metastases
nterface, with SC-RMS and sh1-CXCR3 cells. Melanoma cells (mCherry, red),
up. Chi-square test; *p = 0.04.
ntrol cells.
CR3-KD cells. BV, blood vessel; Met, metastases. Scale bar, 5 mm. Additional
ar, 5 mm.
-RMS or sh1-CXCR3-injected mice (melanoma cells [mCherry, red]). Repre-
rs, 25 mm.
tastases was determined as 2 3 SD 3 102 and was combined with gross in-
2-CXCR3: n = 22, from n = 2 independent biological repeats.
d macrometastases in each treatment group.
XCL10 secretion by astrocytes. CXCL10 signaling supports the brain invasion
d using graphical elements from BioRender.
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The migration of effector T cells into melanoma tumors was
shown to depend on the presence of CXCL10-producing
CD103+ dendritic cells in amousemodel of melanoma and in hu-
man samples of metastatic melanoma (Spranger et al., 2017).
However, while CXCL10 was previously implicated in the recruit-
ment of effector T cells to the brain in inflammatory diseases (Ryu
et al., 2015) and in primary CNS tumors (De Waele et al., 2017),
its function in recruiting T cells to brain metastases is unknown.
Our data indicate that T cells are mobilized by astrocyte-derived
CXCL10, and staining in vivo confirmed that T cells were found in
greater abundance in metastases-bearing brains in comparison
to normal brains. While the CXCL10 pathway is not exclusively
responsible for T cell recruitment, our data suggest that its phys-
iological function in T cell recruitment is hijacked by melanoma
cells to mediate their brain tropism.
The high density of CD3+ or CD8+ T cells was shown to be
correlated with better overall survival in patients with brain me-
tastases (Berghoff et al., 2013, 2015a). Moreover, CXCR3
expression on cytotoxic T lymphocyte (CTLs) was shown to
enhance the therapeutic response to anti-PD-1 treatment in a
mousemodel of melanoma (Chheda et al., 2016). The expression
of CXCR3 on NK cells was also shown to be important for
CXCL10-induced chemoattraction in the anti-tumor response
against solid melanoma tumors (Kim et al., 2018; Wennerberg
et al., 2015). Therefore, future therapeutic targeting of CXCR3
aiming to interfere with astrocyte-melanoma cell crosstalk will
need to be carefully designed to be tumor cell specific to avoid
the abrogation of effector T cell recruitment to the brain.
In summary, we found that neuroinflammation, physiologically
instigated as a protective response of astrocytes to overcome
brain tissue damage, is hijacked by brain-metastasizing tumor
cells to promote their metastatic capacity. CXCL10, which phys-
iologically promotes immunity by recruiting effector T cells, sup-
ports the brain tropism of CXCR3-expressing melanoma cells
and attracts melanoma cells to the metastatic site. Thus, recip-
rocal interactions between metastasizing melanoma cells and
astrocytes are an important determinant in brain metastases.
These findings suggest that the CXCL10-CXCR3 axis is a poten-
tial target for disrupting the formation of a pro-metastatic neuro-
inflammatory brain niche and for preventing melanoma brain
metastatic relapse.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Melanoma cell culture
RMS (Ret-melanoma sorted) cells (Schwartz et al., 2016), their derivative organ-tropic and transduced cell lines were grown in RPMI
media (01-100-1A, BI) supplemented with 10% FCS, 1% Sodium Pyruvate (03-042-1B, BI) and 1% Penicillin-Streptomycin (03-031-
1B, BI), at 37C and 5%CO2. Melanoma cell lines were routinely tested for mycoplasma using the EZ-PCRMycoplasma test kit (20-
700-20, BI).
Ethical statement for use of animals
All experiments involving animals were approved by the Tel Aviv University Institutional Animal Care and Use Committee (IACUC
approval # 01-16-106). 5-8-week-old male C57BL/6RCC (Envigo, Israel) mice were maintained at the SPF facility of the Tel Aviv Uni-
versity or in the conventional animal facilities of the University of Regensburg (Germany).
Isolation of adult mouse primary astrocytes
Isolation of mouse primary astrocytes was performed as previously described (Lifshitz et al., 2013; Schwartz et al., 2016). 5-6-week-
old C57/BL6male mice were euthanized and their brains were harvested, minced and dissociated to single cell suspensions in colla-
genase type-III (LS004182, Worthington Biochemical Corporation) and dispase (04942078001, ROCHE). Demyelination wase2 Cell Reports 28, 1785–1798.e1–e6, August 13, 2019
achieved using percoll (P4937-500ML, Sigma-Aldrich). Isolated cells were seeded in 24 well plates pre-coated with poly-D-lysine
(P7405, Sigma), and cultured in RPMI media supplemented with 10% FCS, 1% Sodium Pyruvate and 1% Penicillin-Streptomycin,
at 37C and 5% CO2. All experiments were performed on low passage (p2-5) cells.
Spontaneous melanoma brain metastasis model
We utilized our previously established spontaneous model of melanoma brain metastasis (Schwartz et al., 2016). A total of 5 3 105
RMS or sBT-RMS cells were re-suspended in PBS andmixed 1:1 with growth factor-reducedMatrigel (356231, BD Biosciences) to a
final volume of 50mL. Mice were anesthetized by isoflurane, and a 29G insulin syringe (BD Biosciences) was used to perform subder-
mal injections at the right flank. Tumors were measured every other day using calipers, and tumor volumes were calculated using the
formula X23Y30:5 (X-smaller diameter, Y-larger diameter). Tumors were excised 2 weeks later, following anesthesia with ketamine
(100 mg/kg) xylazine (10 mg/kg). An incision was made in the skin adjacent to the tumor and it was dissected with clean margins.
Tumor-associated connective tissue and blood vessels were also detached to prevent recurrence, and the incision was sutured
using vicryl threads (J304H, ETHICON). Mice were weighed twice weekly and monitored until relapse or euthanasia.
Spontaneous brain-tropic and lung-tropic RMS cell lines
Following subdermal injection of RMS cells, and primary tumor excision, mice were monitored for spontaneous lung or brain macro-
metastases. Overt macrometastases from lungs and brains (6 months after primary tumor removal) were dissected, cut into small
pieces, cultured for a week, and treated with 2mg/ml Puromycin (MegaPharm, P-1033-SOL), to select for mCherry-expressing mel-
anoma cells. The cells isolated from brain and lungs were designated sBT-RMS (spontaneous brain-tropic RMS) and sLT-RMS
(spontaneous lung-tropic RMS), respectively. Cells were then injected subdermally and monitored closely following primary tumor
excision, as described above. Mice were euthanized 1.5 months post tumor excision, and brains were harvested for RNA extraction
and qPCR analysis of metastases, which validated the organ-specific metastatic capability of the established cell lines.
Intracranial injections
8-week-old male C57BL/6 mice were anesthetized by isoflurane and placed in a Kopf Stereotaxic Alignment System. 500 RMS cells
in 3ml RPMI were injected as previously described (Levy et al., 2012; Schwartz et al., 2016). RPMI SFM was injected as control. Mac-
rometastases-bearing brains were harvested 5 days later and processed for histology or FACS analysis as described below.
Experimental metastases by intracardiac injections
8-week-old male C57BL/6 mice were anesthetized with ketamine/xylazine. Mice were placed under a small animal ultrasound (Vevo
770 High-Resolution In Vivo Micro-Imaging System; VisualSonics Inc.). 105 RMS cells in 100ml PBS were inoculated into the left
ventricle of the heart using a 29G needle. Mice were weighed every other day. Mice injected with RMS CXCR3-KD cells underwent
CT imaging 9 days after injections and were euthanized on day 10. Brains were harvested and hemisected in themidsagittal plane for
gross inspection of macrometastases. Brains were flash frozen for RNA extraction and qPCR analysis of metastases. Three repre-
sentative hemispheres from each group were taken for histological analysis. Mice injected with RMS CXCR3 OE underwent CT im-
aging 14 days after injections and were euthanized on the same day. Total brain RNA was extracted, and brain metastatic load was
assessed by qPCR of mCherry expression, as described below. Metastasis positivity threshold was set at 2 3 SD above the mean
expression in normal control brains. The threshold for macrometastases was set at 2 3 SD 3 102 above the mean expression in
normal control brains. The final cutoff for macrometastases included the detection of macrometastases by gross inspection or by CT.
Brain organotypic co-cultures
These experiments were performed with RMS, sBT-RMS, sLT-RMS, SC-RMS and CXCR3-KD cells, as previously described (Blaz-
quez and Pukrop, 2017; Chuang et al., 2013a). Brains were sliced horizontally into 350 mm sections using a vibratome. Organotypic
brain slices were placed on a 0.4 mm polycarbonate transwell membrane insert in a 6 well plate with 1ml cultivation medium in the
lower well. 105 tumor cells were embedded in 20 mL gel matrix of 30% RPMI medium and 70% ECM gel. RMS-gel matrix mix was
placed into a sterile metallic spacer (3.8mm diameter) adjacent to the cortical region of the organotypic brain slice and incubated for
1h. The spacer was removed, and the 3D tumor spheroid was left to co-culture with the brain slice for 4 days. Immunofluorescent
staining of astrocytes and microglia in the organotypic brain slice was performed. Tumor infiltration grade was determined using
a scoring system: 0 = no infiltration; + < 1/3; ++ = 1/3 - 2/3; +++R 2/3 of the contact area infiltrated by tumor cells.
Human subjects
Patient-derived melanoma brain metastases tissues were collected after written informed consent was obtained from the research
subjects (males, aged 58 and 62) by the Tel Aviv Sourasky Medical Center, under an approved institutional review board (IRB) (0735-
12-TLV).Cell Reports 28, 1785–1798.e1–e6, August 13, 2019 e3
METHOD DETAILS
Astrocyte purity analysis by immunocytochemistry (ICC)
Primary astrocytes (5 3 104 per well) were seeded onto glass coverslips that were pre-coated with poly-D-lysine, in 24 well plates.
Cells were fixedwith 4%PFA for 20min on ice, permeabilizedwith 0.2% triton for 2min, thoroughly washed, incubated in 10%donkey
serum for 30min, and stained with rabbit anti-GFAP (1:500, Z-0334, Agilent), for 1h at room temperature. Cells were then washed and
incubated with Alexa Fluor 488-conjugated donkey anti-rabbit antibody (1:500, 711-545-152, Jackson) for 30min. For CD11b stain-
ing, Fc block (1:50, CD16/CD32 Monoclonal Antibody, 14-0161-86, eBioscience) was applied for 30min, followed by staining with
CD11b-FITC (1:100, 11-01-02 eBioscience) for 1.5h. The coverslips were mounted with DAPI onto microscope slides. Astrocyte pu-
rity was confirmed, as all cells were stained positive for GFAP and negative to microglia marker CD11b.
Astrocyte purity analysis by FACS
For intracellular GFAP staining of cultured primary astrocytes, cells were collected, suspended with Fc block (1:50, CD16/CD32
Monoclonal Antibody, 14-0161-86, eBioscience) in FACS buffer (1% FCS in PBS) and incubated for 40min. Cells were then fixed
and permeabilized using the Fixation/Permeabilization Solution Kit (554714, BD Biosciences), according to the manufacturer’s in-
structions. Following blocking with 2% donkey serum in FACS buffer, the cells were incubated with 50mL BD Perm/Wash buffer
with the GFAP antibody (1:100, Z-0334, Agilent) for 30min at 4C in the dark, with gentle mixing every 2-5min to prevent clumping
and maximize staining efficacy. Cells were then washed and incubated with secondary antibody donkey anti-rabbit 647 (1:500,
711-605-152, Jackson) for 30min. For membranal CD45 and CD11b staining, cells were incubated with a mix of 1:50 Fc block,
CD45-PE-Cy7 (1:200, 25-0451-82, eBioscience) and CD11b-PerCP-Cy5.5 (1:250, 45-0112-82, eBioscience) in FACS buffer for
30min. Prior to FACS analysis, cells were fixed with 4% PFA, washed and re-suspended in FACS buffer. All incubations took place
at 4C, in the dark, and suitable isotype controls were included for each sample. Flow cytometry was performed using CytoFLEX
Platform and data were analyzed using Kaluza 1.2 and FlowJo. Astrocyte purity was confirmed as 98.7% GFAP-positive, and
99.6% negative to immune cell and microglia markers.
Astrocyte purity analysis by qRT-PCR
RNA was extracted from cultured astrocytes and analyzed for the expression of Gfap and Cd11b. Cultured splenocytes from disso-
ciated spleens were used as control. Reverse transcription and qRT-PCR analysis were performed as described below. Astrocytes
were shown to express Gfap, while microglia marker Cd11b expression was undetected.
In vitro astrocyte activation by melanoma-CM
To preparemelanoma-conditionedmedia (CM), 23 105 RMS or sBT-RMS cells were seeded in 10cm plates and incubated for 48h in
serum-free media (SFM). Melanoma-CM was collected, filtered with 0.2 mm filter (Millipore) and used fresh. 3 3 105 astrocytes/well
were seeded in 6 well plates for 24h. Astrocytes were then incubated with melanoma-CM or SFM control for 16h, then washed with
PBS and incubated in fresh SFM for an additional 24h to produce activated astrocyte-CM or normal astrocyte-CM respectively.
Cytokine array
Normal or RMS-activated astrocytes were prepared as above and lysed. 200 mg from each sample was hybridized with the Mouse
Cytokine Array Panel (ARY006, R&D). Results were quantified by the ImageJ software.
ELISA assay
Normal or RMS-activated astrocytes were prepared as above. Media were concentrated using Amicon Ultra-15 Centrifugal Filter
Units 3kDa (MMUFC900324, Millipore) and analyzed in duplicates. Mouse CXCL10/IP-10 Quantikine ELISA kit was used according
to the manufacturer’s instructions (MCX10, R&D). Results were normalized to cell numbers.
Sorting metastases-associated astrocytes (MAA)
Normal and experimental macrometastases-bearing brains were digested with collagenase/dispase, demyelinated and stained with
ACSA-2-APC (1:10, 130-102-315, Miltenyi Biotec) to collect astrocytes. Melanoma cells were excluded with mCherry, immune cells
and microglia were excluded with CD45-FITC (1:200, 11-0451-81, eBioscience) and CD11b-PerCP-Cy5.5 (1:250, 45-0112-80,
eBioscience). Sorting was performed with the BD-FACSAria-II. Astrocyte purity was validated by qPCR analysis of cell type-specific
markers.
Brain tissue preparation for histology
Micewere anesthetizedwith ketamine/xylazine, brainswere harvested andwashed in PBS, then cut in themidsagittal plane and exam-
inedbygross inspection formetastatic lesions. Brainswere incubated for 5h in 4%PFA (ElectronMicroscopySciences) and transferred
to 1% PFA overnight (O/N). Brains were incubated in 0.5M sucrose for 1h, then in 1M sucrose O/N. Brains were incubated in Optimal
Cutting Temperature compound (OCT, Tissue-Tek) for 1h. All incubations were performed at 4C. Brains were embedded in OCT on
dry ice, then stored at 80C. 10 mm serial sections were cut using a cryostat (CM1950, Leica), and slides were stored at 80C.e4 Cell Reports 28, 1785–1798.e1–e6, August 13, 2019
Immunofluorescent tissue staining
Frozen brain tissue sections were incubated at 60C for 20min, washed with PBS, then blocked with Protein block solution (X0909,
DAKO) for 20min. Slides were incubated for 1.5h at RT with rabbit anti-mouse GFAP (Z-0334, Agilent), goat anti-mouse CXCL10
(AF-466-NA, R&D) or rat anti-mouse CD3 (MCA500GA, Bio-Rad), diluted 1:1000, 1:100, and 1:100, respectively. Fluorescently-con-
jugated secondary antibodies donkey anti-rabbit Alexa Fluor 647 (711-605-152, Jackson), donkey anti-goat Dylight-488
(705-486-147, Jackson), donkey anti-rat 647 (712-605-153, Jackson) diluted 1:1000 were applied for 30min at RT. Stained slides
were mounted with DAPI Fluoromount-G (0100-20, Southern Biotech), left to dry O/N at RT and stored at 4C. Images were acquired
using the confocal Leica SP8 platform. For the ITGb4 and nidogen stainings, rat anti-CD104 (553745, BD Biosciences), rabbit anti-
mCherry antibody (b167453, Abcam) and rat anti-Nidogen (ELM1) antibody (sc-33706, Santa Cruz) were diluted 1:200, 1:500 and
1:2000 respectively, and fluorescently-conjugated donkey anti-rabbit rhodamine (711-295-152, Jackson) and donkey anti-rat
DyLight-488 (DkxRt-003-D488NHSX, Jackson) diluted 1:1000 were applied for 30min at RT. Images were acquired using a Nikon
C2+ laser-scanning confocal microscope with a 60 3 /1.4 oil objective or a 20 3 /0.75 air objective.
Human frozen OCT-embedded melanoma brain metastases tissues were cryosectioned into 5mm sections. Immunostaining was
performed using the BOND RX automated immunohistochemistry (IHC) stainer (Leica Biosystems). Slides were incubated in 10%
goat serum and 0.02% Tween-20 in PBS for 30min. Rabbit anti-GFAP (1:500, Z0334, Agilent), mouse anti-human CXCL10 (IP10)
(1:25, ab8098, Abcam) or mouse anti-human CXCR3 (1:100, ab64714, Abcam) antibodies were applied for 1h. Secondary antibodies
goat anti-rabbit Alexa 488 (1:300, b150077, Abcam), and goat anti-mouse Alexa-647 (1:300, ab150115, Abcam) were applied for 1h.
Nuclei were counterstained with ProLong Gold antifade reagent with DAPI (Invitrogen). Images were captured using Evos FL Auto,
Life Technologies microscope, at 40x magnification.
RNA extraction
In all in vivo experiments, RNA was purified using EZ-RNA II kit (20-410-100, BI) according to the manufacturer’s instructions. Total
brains or lungs were homogenized in 1ml denaturation solution A in M tubes (130-096-335, Milteny Biotec) utilizing gentleMACS Dis-
sociator (Miltenyi Biotec). For in vitro experiments, RNA was extracted using the PureLink RNA Mini Kit (12183018A, Invitrogen).
Quantitative real-time PCR (qRT-PCR)
Reverse transcription was performed with qScript (95047-100, Quanta Biosciences) in all experiments. 10ng cDNA were used for
in vitro experiments and 40ng were used for in vivo experiments. qRT-PCR analyses were conducted using PerfeCTa SYBR Green
FastMix ROX (95073-012-4, Quanta Biosciences). Expression results were normalized to Hprt unless otherwise stated, and to the
appropriate control group as indicated (RQ = 2-DDCt).
See Table S1. List of qRT-PCR primers.
Melanoma migration assay
Melanomacellswerecultured inSFM for 48hprior to theexperiment. 13105astrocytes/wellwereseeded in24well platesand24h later,
incubated for 5h in SFM. 600ml SFM was added to the astrocytes (lower chamber) and 5mg/ml anti-CXCL10 (AF-466-NA, R&D) was
added when indicated. 0.8mm pore transwell membrane inserts were placed in the astrocyte-containing wells and 53 104 melanoma
cells in 100ml SFMRPMIwere seeded onto insertmembranes (upper chamber). Experimentswere run in duplicates. 48h later, transwell
membranes were fixated with 4% PFA for 20min on ice, washed with PBS, and carefully cut out and mounted onto microscope slides
withDAPI Fluoromount-G.Microscopepictures ofmembraneswere taken, andmigrated cellswere analyzedwith the ImageJ software.
T cell isolation and migration assay
Spleens were harvested from 5-6-week-old C57/BL6 male mice, minced and dissociated. T cells were isolated using Magnisort
Mouse T Cell Enrichment Kit (8804-6820-74). 1 3 106 T cells in 100ml SFM RPMI were seeded onto 3mm pore size membranes of
24 well transwell inserts. The lower chamber contained SFM, normal astrocyte-CM, RMS-activated astrocyte-CM or sBT-RMS-acti-
vated astrocyte-CM (prepared as described above). Migration was assessed after 5h and experiments were run in duplicates. 5mM
EDTA was added to all wells and media containing migrated cells was collected. Migrated cells were counted using a
hemocytometer.
RMS CXCR3 transduction
The expression of CXCR3 was knocked down in melanoma cells by lentiviral transduction of shRNA. LVRU6GH lentiviral plasmids
containing shRNA for CXCR3 (sh1-CXCR3 GGTTAGTGAACGTCAAGTGCT and sh2-CXCR3 TCAGCCTGAACTTTGACAGAA),
or scrambled control (GCTTCGCGCCGTAGTCTTA) were purchased from GeneCopoeia. CXCL10 knockdown in melanoma cell
lines was performed by cloning previously established (Wightman et al., 2015) shRNA sequences (sh1-CXCL10 TAGATTCCGGATT
CAGACATC and sh2-CXCL10 TTGATGGTCTTAGATTCCGGA) into the LVRU6GH-backbone plasmid. Lentiviral transduction was
performed as previously detailed (Schwartz et al., 2016). Overexpression of CXCR3 was achieved by lentiviral transduction of
RMS cells with backbone plasmid, or with the CXCR3 ORF (Accession number GeneBank: NM_009910, vector pEZLv152). Infected
cells were selected with 2 mg/ml Puromycin and 100 mg/ml Hygromycin (H-270-5-1, ENCO). Validation of silencing was performed
with qPCR prior to experiments.Cell Reports 28, 1785–1798.e1–e6, August 13, 2019 e5
CXCR3 analysis by FACS
RMS, sBT-RMS or CXCR3-KD cells were incubated for 48h in SFM. Cells were collected following 5min incubation with PBS, centri-
fuged and counted. 13 106 cells were resuspended in 100ml FACS buffer (0.5%FCS in PBS). Following blocking, mouse anti-CXCR3
APC antibody (1:10, FAB1685A, R&D) was added. Isotpye controls (1:10, IC006A, R&D) and unstained controls were included for
each sample. Dead cells were excluded either with DAPI (when cells were analyzed fresh) or Zombie viability dye (423113,
BioLegend) when cells were analyzed following fixation with 4% PFA. Flow cytometry was performed using Gallios (Beckman
Coulter, Brea, CA) and CytoFLEX Platform. Data were analyzed using Kaluza 1.2 and FlowJo.
Polyplex formation and electrophoretic mobility shift assay (EMSA)
Two sequences of siRNA against CXCR3 (Cxcr3-siRNA 13.1: CUAGAAACCUCACUUAAACUUUCAA or 13.3: CGUUUUCGAG
CUAUGAGGCUAGUGG) designated siRNA-1 CXCR3 and siRNA-2 CXCR3, respectively, were purchased from IDT. Both siRNA se-
quences were complexed with amphiphilic poly(a)glutamate amine (APA) nanocarrier as previously described (Gibori et al., 2018),
and designated APA:siRNA-1 CXCR3 and APA:siRNA-2 CXCR3 polyplexes. APA:siRNA targeting EGFP was used as negative con-
trol (NC). Evaluation of the optimal N/P ratio (amine groups of APA to phosphate groups of the siRNA) for complexation of APA with
siRNA was performed. 50pmol of siRNA was mixed with increasing amounts of polymer and left to form complexes at room temper-
ature for 30min. DNA loading buffer was added to the samples, which ran for 30min at 100V on a 2% agarose gel.
Dynamic light scattering (DLS) and zeta potential determination
Samples were prepared at APA concentration of 0.1mg/ml in 15mM PBS, all measurements were performed at 25C DLS and zeta
potential measurements analysis was performed using Mobius (Wyatt Technology Corporation, Santa Barbara, CA, USA), equipped
with a 532nm laser and a DLS Fluorescence Filter.
Plasma stability assay
The stability of APA:Cxcr3-siRNA in plasma was evaluated by incubating the polyplexes in 50%mouse plasma for 0.5–24h and elec-
trophoresis was performed as above. Naked siRNA at the same concentration was loaded as control.
Cell viability assay
1.53 104 RMS cells were seeded in 24 well plates. Cells were treated with APA:siRNA-1 CXCR3, APA:siRNA-2 CXCR3 or APA:NC-
siRNA (N/P 2, 50nM) for 24h and counted.
APA:CXCR3 siRNA silencing
The capability of APA:siRNA CXCR3 to inhibit Cxcr3 at the mRNA level was assessed by treating melanoma cells with equivalent
concentrations of 50nM siRNA in APA:siRNA CXCR3 nano-polyplex: 2.53 104 RMS cells were seeded in 6 well plates and incubated
for 24h with the polyplexes. RNA isolation and qPCR were performed as above.
siRNA migration assays
Melanoma cells were incubated for 24hwith the different polyplexes. Migration was analyzed after 24h by fixation and staining (Hema
3 Stain System; Fisher Diagnostics, USA). EVOS FL Automicroscope (Thermo Fisher scientific, USA) and ImageJ software were used
for analysis.
Computed tomography (CT)
Mice were anesthetized by an IP injection of ketamine (100 mg/kg) and xylazine (20 mg/kg), then received an IV injection of 200mL
Omnipaque (iohexol 350mg/mL) to the tail vein. They were then placed in a TomoScope Synergy micro-CT scanner at a resolution
of 100mm, with the following parameters: 40kV X-ray voltage, scan time: 90 s; 3 gantry rotations, radiation dose: 322mGy/cm, each
tube current: 1mAmp. After intracardiac inoculation, computed tomography brain images were acquired on day 9 for shCXCR3-in-
jected mice, and day 14 for CXCR3 OE-injected mice. Identification of macrometastases was validated by multiple planar views of
each suspected lesion and reviewed by a specialist radiologist.
QUANTIFICATION AND STATISTICAL ANALYSIS
The statistical details of experiments, including statistical tests used, number of experiments and mice, can be found in the figure
legends. Student’s t test, One-way or Two-way ANOVA with Tukey’s-post hoc test, or Chi-square were performed to analyze exper-
iments, as appropriate, using GraphPad Prism version 7.00 for Windows. All analyses were two-tailed except for the ELISA result in
Figure 1D and the qPCR in Figure 4F, which were one-tailed. Data were considered significant when p-value < 0.05.e6 Cell Reports 28, 1785–1798.e1–e6, August 13, 2019
